Yoshikawa S, Oh Hora M, Hashimoto R, Nagao T, Peters L, Egawa M, et al. Pivotal role of STIM2, but not STIM1, in IL-4 production by IL-3-stimulated murine basophils. Sci Signal. 2019;12: pubmed publisher

Mishra R, Yadav R, Jones C, Nocadello S, Minasov G, Shuvalova L, et al. Structural and immunological characterization of E. coli derived recombinant CRM197 protein used as carrier in conjugate vaccines. Biosci Rep. 2018;38: pubmed publisher

Fontana M, de Melo G, Anidi C, Hamburger R, Kim C, Lee S, et al. Macrophage Colony Stimulating Factor Derived from CD4+ T Cells Contributes to Control of a Blood-Borne Infection. PLoS Pathog. 2016;12:e1006046 pubmed publisher

Fiorentini G, Banfi R, Dentico P, Moriconi S, Turrisi G, Pelagotti F, et al. Clinical experience of treatment of metastatic melanoma and solid tumours adopting a derivative of diphtheria toxin: cross-reacting material 197. In Vivo. 2013;27:197-202 pubmed

Huang Y, Hung J, Cheung S, Lee H, Chu K, Li S, et al. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci U S A. 2013;110:2517-22 pubmed publisher

Micoli F, Rondini S, Gavini M, Lanzilao L, Medaglini D, Saul A, et al. O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS ONE. 2012;7:e47039 pubmed publisher

Dateoka S, Ohnishi Y, Kakudo K. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer. Med Mol Morphol. 2012;45:91-7 pubmed publisher

Fiorino F, Ciabattini A, Rondini S, Pozzi G, Martin L, Medaglini D. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice. Vaccine. 2012;30:6111-4 pubmed publisher

Tang X, Deng S, Li M, Lu M. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer. Biochem Biophys Res Commun. 2012;422:676-80 pubmed publisher

Malito E, Bursulaya B, Chen C, Lo Surdo P, Picchianti M, Balducci E, et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A. 2012;109:5229-34 pubmed publisher

Lee L, Blake M. Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response. Clin Vaccine Immunol. 2012;19:551-6 pubmed publisher

Findlow H, Borrow R, Andrews N, Waight P, Sheasby E, Matheson M, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom. Pediatr Infect Dis J. 2012;31:616-22 pubmed publisher

Park K. Targeted delivery to monocytes. J Control Release. 2012;158:1 pubmed publisher

Micoli F, Rondini S, Pisoni I, Giannelli C, Di Cioccio V, Costantino P, et al. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi. Vaccine. 2012;30:853-61 pubmed publisher

Kuo Y, Chung C. Transcytosis of CRM197-grafted polybutylcyanoacrylate nanoparticles for delivering zidovudine across human brain-microvascular endothelial cells. Colloids Surf B Biointerfaces. 2012;91:242-9 pubmed publisher

Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10:1621-31 pubmed publisher

Chu C, Boyer J, Schullery D, Gimotty P, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother. 2012;61:629-41 pubmed publisher

Schenk G, Haasnoot P, Centlivre M, Legrand N, Rip J, de Boer A, et al. Efficient CRM197-mediated drug targeting to monocytes. J Control Release. 2012;158:139-47 pubmed publisher

Van Damme P, Kafeja F, Anemona A, Basile V, Hilbert A, De Coster I, et al. Safety, immunogenicity and dose ranging of a new Vi-CRM??? conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE. 2011;6:e25398 pubmed publisher

Rivetti S, Lauriola M, Voltattorni M, Bianchini M, Martini D, Ceccarelli C, et al. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant. Int J Immunopathol Pharmacol. 2011;24:639-49 pubmed

Miyazono K. Ectodomain shedding of HB-EGF: a potential target for cancer therapy. J Biochem. 2012;151:1-3 pubmed publisher

Wang L, Wang P, Liu Y, Xue Y. Regulation of cellular growth, apoptosis, and Akt activity in human U251 glioma cells by a combination of cisplatin with CRM197. Anticancer Drugs. 2012;23:81-9 pubmed publisher

Stefan A, Conti M, Rubboli D, Ravagli L, Presta E, Hochkoeppler A. Overexpression and purification of the recombinant diphtheria toxin variant CRM197 in Escherichia coli. J Biotechnol. 2011;156:245-52 pubmed publisher

Kunami N, Yotsumoto F, Ishitsuka K, Fukami T, Odawara T, Manabe S, et al. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia. Anticancer Res. 2011;31:2483-8 pubmed

Tsujioka H, Fukami T, Yotsumoto F, Ueda T, Hikita S, Takahashi Y, et al. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res. 2011;31:2461-5 pubmed

Safari D, Dekker H, de Jong B, Rijkers G, Kamerling J, Snippe H. Antibody- and cell-mediated immune responses to a synthetic oligosaccharide conjugate vaccine after booster immunization. Vaccine. 2011;29:6498-504 pubmed publisher

Zhang H, Yuan C, Zhang D, Shi H, Li M, Luo Z, et al. A novel combined conjugate vaccine: enhanced immunogenicity of bFGF with CRM197 as a carrier protein. Mol Med Rep. 2011;4:857-63 pubmed publisher

Oberli M, Hecht M, Bindschädler P, Adibekian A, Adam T, Seeberger P. A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol. 2011;18:580-8 pubmed publisher

Caiazza F, Harvey B, Thomas W. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth. Mol Endocrinol. 2010;24:953-68 pubmed publisher